All In Biotech

Drug Trial Radar · NCT03967093

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors

A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors

Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

9

Actual

Start

Apr 15, 2019

Primary completion

Jan 3, 2020

Study completion Jan 17, 2020

Sponsor

Lead sponsor
Bexion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
May 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors. All patients will receive BXQ-350 by intravenous (IV) infusion. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will use the MTD to further assess the safety of BXQ-350 as well as preliminary anti-tumor activity.

Conditions

  • Neoplasms

Interventions

  • BXQ-350Drug

    BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0Time frame: 6 months
  2. Part 1 - Maximum Tolerated DoseTime frame: 6 months
  3. Part 2 - RECISTTime frame: 6 months
  4. Part 2 - RANOTime frame: 6 months
  5. Part 2 - INRCTime frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.